VIPR2

Origem: Wikipédia, a enciclopédia livre.

Receptor de peptídeo intestinal vasoativo ou VIPR2 é um gene relacionado a esquizofrenia.[1]

Referências

Leitura adicional[editar | editar código-fonte]

  • Goetzl EJ, Pankhaniya RR, Gaufo GO; et al. (1998). «Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses.». Ann. N. Y. Acad. Sci. 840: 540–50. PMID 9629281. doi:10.1111/j.1749-6632.1998.tb09593.x 
  • Adamou JE, Aiyar N, Van Horn S, Elshourbagy NA (1995). «Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor.». Biochem. Biophys. Res. Commun. 209 (2): 385–92. PMID 7733904. doi:10.1006/bbrc.1995.1515 
  • Svoboda M, Tastenoy M, Van Rampelbergh J; et al. (1995). «Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts.». Biochem. Biophys. Res. Commun. 205 (3): 1617–24. PMID 7811244. doi:10.1006/bbrc.1994.2852 
  • Inagaki N, Yoshida H, Mizuta M; et al. (1994). «Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells.». Proc. Natl. Acad. Sci. U.S.A. 91 (7): 2679–83. PMC 43433Acessível livremente. PMID 8146174. doi:10.1073/pnas.91.7.2679 
  • Xia M, Gaufo GO, Wang Q; et al. (1996). «Transduction of specific inhibition of HuT 78 human T cell chemotaxis by type I vasoactive intestinal peptide receptors.». J. Immunol. 157 (3): 1132–8. PMID 8757618 
  • Wei Y, Mojsov S (1997). «Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology.». J. Neuroendocrinol. 8 (11): 811–7. PMID 8933357. doi:10.1046/j.1365-2826.1996.05191.x 
  • Mackay M, Fantes J, Scherer S; et al. (1997). «Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: a possible contributor to the holoprosencephaly 3 phenotype.». Genomics. 37 (3): 345–53. PMID 8938447. doi:10.1006/geno.1996.0569 
  • Nicole P, Du K, Couvineau A, Laburthe M (1998). «Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.». J. Pharmacol. Exp. Ther. 284 (2): 744–50. PMID 9454823 
  • Dewit D, Gourlet P, Amraoui Z; et al. (1998). «The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes.». Immunol. Lett. 60 (1): 57–60. PMID 9541464. doi:10.1016/S0165-2478(97)00129-6 
  • Lutz EM, Shen S, Mackay M; et al. (1999). «Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2.». FEBS Lett. 458 (2): 197–203. PMID 10481065. doi:10.1016/S0014-5793(99)01135-7 
  • Busto R, Prieto JC, Bodega G; et al. (2000). «Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung.». Peptides. 21 (2): 265–9. PMID 10764955. doi:10.1016/S0196-9781(99)00202-8 
  • Nicole P, Lins L, Rouyer-Fessard C; et al. (2000). «Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide.». J. Biol. Chem. 275 (31): 24003–12. PMID 10801840. doi:10.1074/jbc.M002325200 
  • Bajo AM, Juarranz MG, Valenzuela P; et al. (2001). «Expression of vasoactive intestinal peptide (VIP) receptors in human uterus.». Peptides. 21 (9): 1383–8. PMID 11072126. doi:10.1016/S0196-9781(00)00282-5 
  • Lara-Marquez M, O'Dorisio M, O'Dorisio T; et al. (2001). «Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.». J. Immunol. 166 (4): 2522–30. PMID 11160313 
  • Lara-Marquez ML, O'Dorisio MS, Karacay B (2001). «Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes.». Ann. N. Y. Acad. Sci. 921: 45–54. PMID 11193874. doi:10.1111/j.1749-6632.2000.tb06950.x 
  • Groneberg DA, Hartmann P, Dinh QT, Fischer A (2001). «Expression and distribution of vasoactive intestinal polypeptide receptor VPAC(2) mRNA in human airways.». Lab. Invest. 81 (5): 749–55. PMID 11351046. doi:10.1038/labinvest.3780283 
  • Juarranz MG, Bolaños O, Gutiérrez-Cañas I; et al. (2002). «Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.». Cell. Signal. 13 (12): 887–94. PMID 11728828. doi:10.1016/S0898-6568(01)00199-1 
  • Fischer TC, Dinh QT, Peiser C; et al. (2002). «Simultaneous detection of receptor mRNA and ligand protein in human skin tissues.». J. Cutan. Pathol. 29 (2): 65–71. PMID 12150135. doi:10.1034/j.1600-0560.2002.290201.x 
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). «Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.». Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. PMC 139241Acessível livremente. PMID 12477932. doi:10.1073/pnas.242603899